XML 34 R17.htm IDEA: XBRL DOCUMENT
v3.25.3

Investment in Day Three Labs Inc. | 12 Months Ended
--- | ---
Jul. 31, 2025
Investment in Day Three Labs Inc. [Abstract] |
INVESTMENT IN DAY THREE LABS INC. | NOTE 13 – INVESTMENT IN DAY THREE LABS INC. Initial investment in Day Three On April 7, 2023, the Company entered into a Common Stock Purchase Agreement (the “Day Three Purchase Agreement”) with Day Three. Day Three is a company which reimagines existing cannabis offerings with technology and innovation like Unlokt™ to bring to market better, cleaner, more precise and predictable products. Pursuant to the Day Three Purchase Agreement, the Company purchased 4,302 shares of common stock, post DTL Reverse Stock Split (as defined below), representing 38% of the outstanding shares of common stock of Day Three (33% on a fully diluted basis), for a purchase price of $3.0 million. The Company also received a warrant exercisable for 7,529 shares of common stock, post DTL Reverse Stock Split, which expires five years from the date of issuance or earlier based on the occurrence of certain events as defined in the Day Three Purchase Agreement (the “Day Three Warrant”). Prior to January 2024, the Company accounted for this investment as an equity method investment in accordance with the guidance in ASC 323, Investments – Equity Method and Joint Ventures. The Company determined that a 38% ownership interest in Day Three and its right to designate two members of the Board of Directors of Day Three (out of a current total of seven members) indicates that the Company is able to exercise significant influence. The Company determined that Day Three is a VIE; however, the Company determined that, prior to January 2024, it was not the primary beneficiary as it did not have the power to direct the activities that most significantly impacted Day Three’s economic performance. The Company has therefore concluded it was not required to consolidate Day Three. The Company used the equity method of accounting to record its investment in Day Three. Day Three’s fiscal year ends on December 31 and, as a result, the Company recognized its share of Day Three’s earnings/loss on a one-month lag. For the year ended July 31, 2024, the Company recognized approximately $422 thousand of equity in loss of Day Three, based on its proportionate share of Day Three’s results through January 2, 2024, the effective date of the Day Three Acquisition. The assets and operations of Day Three are not significant to the Company’s assets or operations. Acquisition of Day Three In January 2024, the Company entered into a series of transactions with Day Three and certain shareholders to purchase an aggregate of 13,771 shares of common stock, post DTL Reverse Stock Split, of Day Three, acquiring a controlling interest of Day Three (the “Day Three Acquisition”). Day Three has options and warrants outstanding that, if and when exercised, could dilute the Company’s ownership interest in Day Three. In connection with the Day Three Acquisition, the Day Three Warrant was terminated. The acquisition date was determined to be January 2, 2024, which is the date that Rafael obtained a controlling interest of the common stock of Day Three. The Day Three Acquisition is being accounted for as a business combination in accordance with ASC 805. During the period of October 2023 through January 2024, the Company advanced $250 thousand to Day Three pursuant to a promissory note (the “Day Three Note I”), $150 thousand to Day Three pursuant to a promissory note (the “Day Three Note II”), $1.0 million to Day Three pursuant to a third promissory note (the “Day Three Note III”), and approximately $589 thousand to Day Three pursuant to a fourth promissory note (the “Day Three Note IV”) (collectively, the “Day Three Promissory Notes”). The Day Three Promissory Notes accrue interest at rates of between 5.01% and 5.19% per annum. The aggregate consideration of the Day Three Acquisition was $3.1 million, which consisted of 1) cash consideration of $0.2 million, 2) accrued consideration of $0.2 million, 3) the exchange of principal and accrued interest amounts totaling to $2.0 million owed by Day Three to the Company pursuant to the Day Three Promissory Notes for common stock, and 4) the fair value of previously held interests in Day Three of $0.7 million. The following table summarizes the purchase consideration transferred in the Day Three Acquisition as defined in ASC 805:
(in thousands) |  | Purchase Consideration |
Cash consideration |  | $ | 200 |
Accrued consideration |  |  | 200 |
Exchange of Day Three Promissory Notes for Common Stock |  |  | 2,000 |
Fair value of previously held interests(1) |  |  | 742 |
Total purchase consideration |  | $ | 3,142 |
(1) | The Company remeasured its previously held equity interest in Day Three immediately before the Day Three Acquisition, previously accounted for under the equity method of accounting, to its fair value (determined using the implied enterprise value based on the purchase price multiplied by the ratio of the number of shares previously held to total shares, as of the acquisition date) and recognized a loss of $1.6 million recorded on the consolidated statements of operations and comprehensive loss as a loss on initial investment in Day Three upon acquisition during the quarter ended January 31, 2024.
The following table summarizes the fair values of the assets acquired and liabilities assumed in the Day Three Acquisition as of the acquisition date:
(in thousands) |  | January 2, 2024 |
Cash and cash equivalents |  | $ | 1,499 |
Accounts receivable |  |  | 63 |
Prepaid expenses and other current assets |  |  | 77 |
Property and equipment |  |  | 408 |
Goodwill |  |  | 3,050 |
Identifiable intangible assets |  |  | 2,180 |
Accounts payable |  |  | (386 | )
Accrued expenses |  |  | (98 | )
Installment note payable |  |  | (2,500 | )
Total fair value of net assets acquired |  |  | 4,293 |
Less: noncontrolling interest |  |  | (1,151 | )
Net assets acquired attributable to Rafael |  | $ | 3,142 |
During the year ended July 31, 2024, the Company recognized an adjustment which changed the fair value of certain acquired liabilities and goodwill as a result of obtaining additional information about the estimated liabilities. The noncontrolling interest was recognized at fair value, which was determined using the implied enterprise value based on the purchase price multiplied by the ratio of the number of shares owned by minority holders to total shares, as of the acquisition date. Intangible assets acquired primarily include patents, technology licenses and non-compete agreements. The weighted average amortization period for the acquired intangible assets is approximately 14.7 years. On January 23, 2024, Day Three entered into an asset purchase agreement for the sale of certain patents for $280 thousand. Included in the acquired liabilities assumed in the Day Three Acquisition is a non-interest bearing installment note payable of $2.5 million (the “DTLM Note Payable”). The installment note was recognized by Day Three in relation to a 2021 asset purchase agreement for certain patents related to extraction technology which are used in Day Three Lab Manufacturing’s Infusion Technology services. The assumed installment note payable had a balance of $800 thousand due January 2024 (which was paid in January 2024) and the remaining $1.7 million due in November 2024. The DTLM Note Payable was fully settled as part of the DTLM Sale Transaction (defined below). On March 20, 2024, Day Three amended and restated its certificate of incorporation to, among other things, effect a one-for-one-thousand reverse split of all of Day Three’s common stock (the “DTL Reverse Stock Split”). On May 1, 2024, Rafael entered into a stock purchase agreement with Day Three to purchase 7,194 shares of common stock at a purchase price of $173.75 per share for an aggregate purchase price of $1.25 million, $1 million of which was funded through the relief of an existing intercompany receivable. As a result of the transaction, and as of July 31, 2025, Rafael has an 84% ownership interest in Day Three. Due to reductions in certain operations including a layoff, the Company concluded that in accordance with ASC 350 and ASC 360, a triggering event occurred during November 2024, which required the Company to assess if goodwill or long-lived assets were impaired. In accordance with ASC 360, the Company completed an analysis and determined that the expected undiscounted cash flows of the long-lived asset group exceeded its carrying amount, indicating that the long-lived assets were not impaired. In accordance with ASC 350, the Company performed a quantitative goodwill impairment test, which indicated that the carrying amount of the reporting unit exceeded the estimated fair value of the reporting unit, indicating that the goodwill of the reporting unit was impaired. The Company recorded an impairment charge of $3.1 million related to goodwill during the year ended July 31, 2025. See Note 18 for more information. In March 2025, Day Three Labs Manufacturing entered into a series of transactions (the “DTLM Sale Transactions”) with SoRSE and the holder of the DTLM Note Payable pursuant to which they sold certain assets in exchange for a $500 thousand non-interest bearing convertible promissory note (see Note 11) and were relieved of the liability under the DTLM Note Payable in exchange for shares of Day Three Labs Manufacturing common stock. As a result of the DTLM Sale Transactions, which were contemplated and accounted for as a single transaction, the holder of the DTLM Note Payable owns 20% of the outstanding shares of Day Three Labs Manufacturing. Pursuant to the DTLM Sale Transactions, Day Three Labs Manufacturing also licensed specific applications of their Unlokt™ technology patents to SoRSE, effective through the patents’ expiration. The Company recognized a gain of $30 thousand as a result of the DTLM Sale Transactions which is included in other income, net on the consolidated statements of operations and comprehensive loss during the year ended July 31, 2025.

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentCompanyAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration